Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02295787

Intranasal Ketamine for Late-Life Depression and Suicidal Ideation

Status
Withdrawn
Phase
Phase 4
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Massachusetts General Hospital · Academic / Other
Sex
All
Age
65 Years
Healthy volunteers
Not accepted

Summary

The investigators of this study plan to investigate the feasibility and efficacy of repeated doses of intranasal ketamine in severely depressed patients who are at least 65 years of age and experiencing suicidal ideation. The results of the study could lead to development of new strategies for treating depression.

Conditions

Interventions

TypeNameDescription
DRUGKetamineIntranasal ketamine for late-life depression and suicidal ideation.
DRUGPlacebo

Timeline

Start date
2015-07-01
Primary completion
2015-07-01
Completion
2015-07-01
First posted
2014-11-20
Last updated
2017-03-03

Source: ClinicalTrials.gov record NCT02295787. Inclusion in this directory is not an endorsement.

Intranasal Ketamine for Late-Life Depression and Suicidal Ideation (NCT02295787) · Clinical Trials Directory